Rotigotine transdermal system: a short review
Authors Sabine Bunten, Svenja Happe
Published 15 December 2006 Volume 2006:2(4) Pages 421—426
Sabine Bunten, Svenja Happe
Department of Clinical Neurophysiology, Klinikum Bremen-Ost/University of Göttingen, Germany
Abstract: Rotigotine (Neupro®) is a new non-ergolinic dopamine agonist transdermal patch that can be applied once daily. To date, it is approved for the treatment of early Parkinson’s disease as monotherapy and has been shown to be effective in the treatment of advancedstage Parkinson’s disease and restless legs syndrome in several clinical trials. This review gives an overview of physical, chemical, and pharmaceutical characteristics, pharmacokinetics, biotransformation and elimination, drug interactions, and adverse events of rotigotine. Further, the rationale for the treatment of Parkinson’s disease and restless legs syndrome with rotigotine is discussed.
Keywords: rotigotine, transdermal patch, Parkinson’s disease, restless legs syndrome